Displaying 37 - 48 of 51
Metabolism, Alcohol & Toxicity
8

Sanofi: "Global Liver Health Forum 2023" - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
8

Sanofi: "Global Liver Health Forum 2023" - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
8

Sanofi: "Global Liver Health Forum 2023" - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
6

Sanofi: "Global Liver Health Forum 2023 – Expert's exchange" - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
8

Sanofi: "Global Liver Health Forum 2023" - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
8

Sanofi: "Global Liver Health Forum 2023" - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
6

Takeda: "Alpha-1 antitrypsin deficiency (AATD) - Associated liver disease: More common than you may think" - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
6

Takeda: "Alpha-1 antitrypsin deficiency (AATD) - Associated liver disease: More common than you may think" - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
6

Takeda: "Alpha-1 antitrypsin deficiency (AATD) - Associated liver disease: More common than you may think" - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
6

Takeda: "Alpha-1 antitrypsin deficiency (AATD) - Associated liver disease: More common than you may think" - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
6

Takeda: "Alpha-1 antitrypsin deficiency (AATD) - Associated liver disease: More common than you may think" - EASL Congress 2023

View
Immune-Mediated and Cholestatic Diseases
4

Albireo Pharma: Idiopathic Cholestasis and Targeted Next-Generation Sequencing Panels: A Case-Based Approach - ILC 2022

View
Displaying 37 - 48 of 51